EuropaBio Event: The Role of Biotechnology in Europe’s Responsible Innovation
On Thursday 9 Dec. 2010, a broad range of regulators, CEOs, VCs, stakeholders, industry representatives and journalists met to share their perspectives on the role of biotechnology in contributing to the creation of Europe’s Innovation Union. Speakers from across Europe in the healthcare, industrial and agricultural sectors communicated their views on how biotechnology is creating more jobs, improving lives and building a greener and healthier society. They outlined how these changes are being made through benefits in major areas of concern for European citizens including healthy living and ageing, climate change and food and energy security. Speaking at the event, EuropaBio Chairman, Andrea Rappagliosi said: “Biotechnology has the potential to help make Europe a world-class science performer providing smart, sustainable and inclusive solutions for citizens, patients and consumers for 2020 and beyond. Our industry is willing to be held accountable for delivering products and solutions that have a demonstrable value in order to retain and strengthen state-of-the-art research and development in Europe. We are committed to playing our role in this process together with regulators, civil society and a broad range of stakeholders.” In a video address, specially prepared for the event, President Barroso underlined that “Europe needs an innovative R&D oriented and responsible biotech industry. An industry which is rooted in the middle of our societies, because it offers concrete …
Video Rating: 0 / 5
CONTINUING TO SUPPORT THE NATION’S EMERGING SECTORS As an innovative financier and development facilitator of the ICT sector, MDV is now extending its portfolio into the rapidly emerging biotechnology sector. MDV has established its own independent team of credit and research professionals and a dedicated fund towards advancing this vibrant sector as one of the main engines of growth for the nation’s economy. Your independent vision and leadership with full control. Building a company takes enormous effort and determination from the start. It will ultimately be your vision and leadership that will lead your company to success. MDV takes no stake in your company. Instead we offer the following advantages compared to venture capitalists and other financiers: * Clear and transparent exit mechanism ie repayment of financing * Flexible repayment periods * Independent of stock market conditions * Independent of your company valuation * Maximising returns to shareholders, including existing Venture Capital investors Your application process is accelerated due to our highly-efficient procedures. Upon securing your Biotech project, you would want someone to act on it fast. With complete documentation, we will process your application within a short timeframe. Biotech projects are very time-sensitive and work best when implemented within a specific window of opportunity. Due to our in-depth knowledge of the industry and highly-effective procedures, MDV works fast so that you can …